4f9v: Difference between revisions
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Structure of C113A/C136A mutant variant of glycosylated glutaminyl cyclase from Drosophila melanogaster== | ==Structure of C113A/C136A mutant variant of glycosylated glutaminyl cyclase from Drosophila melanogaster== | ||
<StructureSection load='4f9v' size='340' side='right' caption='[[4f9v]], [[Resolution|resolution]] 2.10Å' scene=''> | <StructureSection load='4f9v' size='340' side='right'caption='[[4f9v]], [[Resolution|resolution]] 2.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[4f9v]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[4f9v]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Drosophila_melanogaster Drosophila melanogaster]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4F9V OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4F9V FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=PBD:1-(3,4-DIMETHOXYPHENYL)-3-[3-(1H-IMIDAZOL-1-YL)PROPYL]THIOUREA'>PBD</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=PBD:1-(3,4-DIMETHOXYPHENYL)-3-[3-(1H-IMIDAZOL-1-YL)PROPYL]THIOUREA'>PBD</scene>, <scene name='pdbligand=PEG:DI(HYDROXYETHYL)ETHER'>PEG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4f9v FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4f9v OCA], [https://pdbe.org/4f9v PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4f9v RCSB], [https://www.ebi.ac.uk/pdbsum/4f9v PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4f9v ProSAT]</span></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | |||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/QPCT1_DROME QPCT1_DROME] Acts as a glutaminyl-peptide cyclotransferase (PubMed:17722885, PubMed:22897232). Responsible for the biosynthesis of pyroglutamyl peptides (By similarity). Might be more efficient in the conversion of tri and tetrapeptides in vitro (PubMed:17722885). Might have a relative preference for substrates containing hydrophobic amino acids in vitro (PubMed:17722885).[UniProtKB:Q16769]<ref>PMID:17722885</ref> <ref>PMID:22897232</ref> | |||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
| Line 16: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4f9v" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Glutaminyl cyclase|Glutaminyl cyclase]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
| Line 21: | Line 27: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Drosophila melanogaster]] | [[Category: Drosophila melanogaster]] | ||
[[Category: Koch | [[Category: Large Structures]] | ||
[[Category: Kolenko | [[Category: Koch B]] | ||
[[Category: Ruiz-Carilo | [[Category: Kolenko P]] | ||
[[Category: Stubbs | [[Category: Ruiz-Carilo D]] | ||
[[Category: Stubbs MT]] | |||
Latest revision as of 09:30, 17 October 2024
Structure of C113A/C136A mutant variant of glycosylated glutaminyl cyclase from Drosophila melanogasterStructure of C113A/C136A mutant variant of glycosylated glutaminyl cyclase from Drosophila melanogaster
Structural highlights
FunctionQPCT1_DROME Acts as a glutaminyl-peptide cyclotransferase (PubMed:17722885, PubMed:22897232). Responsible for the biosynthesis of pyroglutamyl peptides (By similarity). Might be more efficient in the conversion of tri and tetrapeptides in vitro (PubMed:17722885). Might have a relative preference for substrates containing hydrophobic amino acids in vitro (PubMed:17722885).[UniProtKB:Q16769][1] [2] Publication Abstract from PubMedGlutaminyl cyclases (QCs), which catalyze the formation of pyroglutamic acid (pGlu) at the N-terminus of a variety of peptides and proteins, have attracted particular attention for their potential role in Alzheimer's disease. In a transgenic Drosophila melanogaster (Dm) fruit fly model, oral application of the potent competitive QC inhibitor PBD150 was shown to reduce the burden of pGlu-modified Abeta. In contrast to mammals such as humans and rodents, there are at least three DmQC species, one of which (isoDromeQC) is localized to mitochondria, whereas DromeQC and an isoDromeQC splice variant possess signal peptides for secretion. Here we present the recombinant expression, characterization and crystal structure determination of mature DromeQC and isoDromeQC, revealing a similar overall fold to mammalian QCs. In the case of isoDromeQC, the putative extended substrate binding site might be affected by proximity of the N-terminal residues. PBD150 inhibition of DromeQC is roughly one order of magnitude lower than that of the human and murine QCs. The inhibitor binds to isoDromeQC in a similar fashion to that observed for human QCs, whereas it adopts alternative binding modes in a DromeQC variant lacking the conserved cysteines near to the active center and shows a disordered dimethoxyphenyl moiety in wild type DromeQC, providing an explanation for the lower affinity. Our biophysical and structural data suggest that isoDromeQC and human QC are similar with regard to functional aspects. The two Dm enzymes represent a suitable model for further in depth analysis of the catalytic mechanism of animal QCs, and isoDromeQC might serve as a model system for structure based design of potential AD therapeutics. Crystal Structures of Glutaminyl Cyclases from Drosophila melanogaster Reveal Active Site Conservation between Insect and Mammalian QCs.,Koch B, Kolenko P, Buchholz M, Ruiz Carrillo D, Parthier C, Wermann M, Rahfeld JU, Reuter G, Schilling S, Stubbs MT, Demuth HU Biochemistry. 2012 Aug 16. PMID:22897232[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||